Changes in Siegfried’s Executive CommitteeMedia Release
Siegfried announces two changes to its Executive Committee
Siegfried acquires majority stake in DiNAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapiesAd Hoc
Siegfried announces the acquisition of a 95% stake in DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies
Siegfried confirmed in the Dow Jones Sustainability Index Europe for the second consecutive yearMedia Release
Siegfried is proud to announce that it has been confirmed as a member of the Dow Jones Sustainability Index (DJSI) Europe for the second consecutive year.
Siegfried Announces Change in its Board of DirectorsAd Hoc
After 10 years on the Board of Directors of the Siegfried Group, Board member Colin Bond has decided not to stand for re-election at the company’s upcoming Annual General Meeting (AGM) on 20 April 2023.